RecruitingNot ApplicableNCT06923618

Cancer of the Lung And SeneScencE - Prospective Cohort 1

Identification of Aging Biomarkers for Better Tailoring of Cancer Treatment in Older Patients With Lung Cancer: a Multicenter Clinico-biological Cohort Study


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

385 participants

Start Date

Jul 9, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The main objective is to identify and assess the predictive value of ageing and senescence biomarkers (methylome, telomeres, inflammageing) and senescent cells in tissues to improve prognosis assessment older patients with locally or locally-advanced Non-Small Cell Lung Cancer (NSCLC).


Eligibility

Min Age: 70 Years

Inclusion Criteria5

  • Patients 70 years and over
  • Local or locally advanced (Clinic stage I-IIIA) NSCLC (clinically (or radiologically) suspected or histologically proven)
  • Surgical Curative Intent
  • Signed informed Consent (or signed by the curator or tutorship)
  • Affiliated to social security administrative care service

Exclusion Criteria3

  • Synchronous cancer (histologically proven or strongly suspected non-lung cancer in the 6 months prior to inclusion (excluding basal cell cancer and prostate cancer with local treatment (radiotherapy or surgery) or active surveillance without systemic treatment (chemotherapy, hormone therapy)).
  • Subject deprived of liberty by judicial or administrative decision or patient under guardianship
  • Subject unable to understand the purpose and conditions of the study and unable to give consent

Interventions

BIOLOGICALBlood samples

Blood samples (5 ml) during surgery or within 3 days before.


Locations(1)

Henri Mondor Hospital

Créteil, Île-de-France Region, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06923618


Related Trials